BSE Live
Apr 16, 16:01Prev. Close
80.40
Open Price
80.40
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 16, 15:51Prev. Close
80.27
Open Price
81.44
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
82.70 (379)
| Cash Flow of Anuh Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 61.01 | 78.31 | 47.47 | 39.12 | 38.55 | |
| Net CashFlow From Operating Activities | 37.12 | 12.93 | 53.90 | 28.86 | -18.73 | |
| Net Cash Used In Investing Activities | -19.91 | 0.92 | -43.48 | -7.82 | 52.20 | |
| Net Cash Used From Financing Activities | -4.86 | -8.57 | -12.29 | -19.45 | -33.12 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 12.36 | 5.27 | -1.87 | 1.60 | 0.35 | |
| Cash And Cash Equivalents Begin of Year | 7.20 | 1.93 | 3.80 | 2.20 | 1.85 | |
| Cash And Cash Equivalents End Of Year | 19.56 | 7.20 | 1.93 | 3.80 | 2.20 |
10.02.2026
Anuh Pharma Standalone December 2025 Net Sales at Rs 197.18 crore, up 23.61% Y-o-Y
12.11.2025
Anuh Pharma Standalone September 2025 Net Sales at Rs 185.88 crore, up 12.01% Y-o-Y
22.08.2025
Anuh Pharma Standalone June 2025 Net Sales at Rs 186.48 crore, up 35.22% Y-o-Y
27.05.2025
Anuh Pharma Standalone March 2025 Net Sales at Rs 198.14 crore, up 20.9% Y-o-Y
10.02.2026
Anuh Pharma Standalone December 2025 Net Sales at Rs 197.18 crore, up 23.61% Y-o-Y
12.11.2025
Anuh Pharma Standalone September 2025 Net Sales at Rs 185.88 crore, up 12.01% Y-o-Y
22.08.2025
Anuh Pharma Standalone June 2025 Net Sales at Rs 186.48 crore, up 35.22% Y-o-Y
27.05.2025
Anuh Pharma Standalone March 2025 Net Sales at Rs 198.14 crore, up 20.9% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth